Biorem Inc Stock Performance
| BRM Stock | CAD 3.01 0.02 0.67% |
On a scale of 0 to 100, BioRem holds a performance score of 12. The firm shows a Beta (market volatility) of 1.36, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, BioRem will likely underperform. Please check BioRem's sortino ratio, skewness, period momentum indicator, as well as the relationship between the potential upside and rate of daily change , to make a quick decision on whether BioRem's price patterns will revert.
Risk-Adjusted Performance
12 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in BioRem Inc are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, BioRem showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:4 | Last Split Date 2005-01-21 |
1 | BioRem Third Quarter 2024 Earnings EPS CA0.14 - Yahoo Finance | 11/08/2024 |
| Begin Period Cash Flow | 3.8 M |
BioRem |
BioRem Relative Risk vs. Return Landscape
If you would invest 221.00 in BioRem Inc on August 28, 2024 and sell it today you would earn a total of 80.00 from holding BioRem Inc or generate 36.2% return on investment over 90 days. BioRem Inc is currently producing 0.5483% returns and takes up 3.4451% volatility of returns over 90 trading days. Put another way, 30% of traded stocks are less volatile than BioRem, and 90% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
BioRem Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioRem's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as BioRem Inc, and traders can use it to determine the average amount a BioRem's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1592
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BRM | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.45 actual daily | 30 70% of assets are more volatile |
Expected Return
| 0.55 actual daily | 10 90% of assets have higher returns |
Risk-Adjusted Return
| 0.16 actual daily | 12 88% of assets perform better |
Based on monthly moving average BioRem is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioRem by adding it to a well-diversified portfolio.
BioRem Fundamentals Growth
BioRem Stock prices reflect investors' perceptions of the future prospects and financial health of BioRem, and BioRem fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioRem Stock performance.
| Return On Equity | 0.6 | ||||
| Return On Asset | 0.15 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 39.9 M | ||||
| Shares Outstanding | 15.8 M | ||||
| Price To Earning | 3.01 X | ||||
| Price To Book | 4.36 X | ||||
| Price To Sales | 1.53 X | ||||
| Revenue | 25.17 M | ||||
| Gross Profit | 6.24 M | ||||
| EBITDA | 3.47 M | ||||
| Net Income | 2.18 M | ||||
| Cash And Equivalents | 5.75 M | ||||
| Cash Per Share | 0.16 X | ||||
| Total Debt | 4.19 M | ||||
| Debt To Equity | 1.05 % | ||||
| Current Ratio | 2.24 X | ||||
| Book Value Per Share | 0.43 X | ||||
| Cash Flow From Operations | 490.03 K | ||||
| Earnings Per Share | 0.29 X | ||||
| Market Capitalization | 46.45 M | ||||
| Total Asset | 24.08 M | ||||
| Retained Earnings | (1.92 M) | ||||
| Working Capital | 6.71 M | ||||
About BioRem Performance
Evaluating BioRem's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if BioRem has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BioRem has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 18.13 | 24.39 | |
| Return On Tangible Assets | 0.09 | 0.10 | |
| Return On Capital Employed | 0.30 | 0.32 | |
| Return On Assets | 0.09 | 0.10 | |
| Return On Equity | 0.32 | 0.34 |
Things to note about BioRem Inc performance evaluation
Checking the ongoing alerts about BioRem for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BioRem Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioRem Inc appears to be risky and price may revert if volatility continues | |
| BioRem Inc is unlikely to experience financial distress in the next 2 years | |
| Latest headline from news.google.com: BioRem Third Quarter 2024 Earnings EPS CA0.14 - Yahoo Finance |
- Analyzing BioRem's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioRem's stock is overvalued or undervalued compared to its peers.
- Examining BioRem's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioRem's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioRem's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioRem's stock. These opinions can provide insight into BioRem's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for BioRem Stock Analysis
When running BioRem's price analysis, check to measure BioRem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioRem is operating at the current time. Most of BioRem's value examination focuses on studying past and present price action to predict the probability of BioRem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioRem's price. Additionally, you may evaluate how the addition of BioRem to your portfolios can decrease your overall portfolio volatility.